HIF-1: Master and commander of the hypoxic world: A pharmacological approach to its regulation by siRNAs

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 971-980

  Mazure, Nathalie M ^a   Brahimi Horn, M Christiane ^a   Berta, Mélanie A ^a   Benizri, Emmanuel ^a   Bilton, Rebecca L ^a   Dayan, Frédéric ^a   Ginouvès, Amandine ^a   Berra, Edurne ^a   Pouysségur, Jacques ^a  

^a CENTRE DE BIOCHIMIE   (France)

Author keywords

ARD1; arrest defective 1 protein; CBP p300 interacting transactivator with ED rich tail 2; CITED 2; factor inhibiting HIF 1; FIH; HIF 1; hypoxia inducible factor 1; MAPK; mitogen activated protein kinase; PHD; prolyl hydroxylase domain protein; SUMO

Indexed keywords

ARREST DEFECTIVE 1 PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P300; SMALL INTERFERING RNA; SUMO 1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CELL VIABILITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CORRELATION FUNCTION; GENETIC PROCEDURES; HOMEOSTASIS; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REGULATORY MECHANISM; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL HYPOXIA; DNA-BINDING PROTEINS; GTP-BINDING PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NITRIC OXIDE; NUCLEAR PROTEINS; OXYGEN; PROCOLLAGEN-PROLINE DIOXYGENASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 4143110440     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.04.022     Document Type: Conference Paper

References (67)

1. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:2003;721-732
2. Semenza G.L., Agani F., Iyer N., Kotch L., Laughner E., Leung S., et al. Regulation of cardiovascular development and physiology by hypoxia- inducible factor 1. Ann. N Y Acad Sci. 874:1999;262-268
3. Kotch L.E., Iyer N.V., Laughner E., Semenza G.L. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev. Biol. 209:1999;254-267
4. Chen J., Zhao S., Nakada K., Kuge Y., Tamaki N., Okada F., et al. Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am. J. Pathol. 162:2003;1283-1291
5. Semenza G.L. Involvement of hypoxia-inducible factor 1 in human cancer. Int. Med. 41:2002;79-83
6. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8:2002;S62-67
7. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272:1997;19253-19260
8. Gothie E., Richard D.E., Berra E., Pages G., Pouyssegur J. Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J. Biol. Chem. 275:2000;6922-6927
9. Masson N., Willam C., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20:2001;5197-5206
10. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54
11. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22:2003;4082-4090
12. Metzen E., Berchner-Pfannschmidt U., Stengel P., Marxsen J.H., Stolze I., Klinger M., et al. Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing. J. Cell Sci. 116:2003;1319-1326
13. Berra E., Richard D.E., Gothie E., Pouyssegur J. HIF-1-dependent transcriptional activity is required for oxygen- mediated HIF-1alpha degradation. FEBS Lett. 491:2001;85-90
14. Kaelin W.G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:2002;673-682
15. Friedrich C.A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 10:2001;763-777
16. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1999;1822-1833
17. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275
18. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:2000;423-427
19. Hughson M.D., He Z., Liu S., Coleman J., Shingleton W.B. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene. Cancer Genet Cytogenet. 143:2003;145-153
20. Bonicalzi M.E., Groulx I., de Paulsen N., Lee S. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 276:2001;1407-1416
21. Groulx I., Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol Cell Biol. 22:2002;5319-5336
22. Berra E., Roux D., Richard D.E., Pouyssegur J. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2:2001;615-620
23. Li Z., Wang D., Na X., Schoen S.R., Messing E.M., Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J. 22:2003;1857-1867
24. Mahon P.C., Hirota K., Semenza G.L. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15:2001;2675-2686
25. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia- inducible factor 1alpha. Genes Dev. 14:2000;34-44
26. Chen D., Li M., Luo J., Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J. Biol. Chem. 278:2003;13595-13598
27. Neuwald A.F., Landsman D. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem Sci. 22:1997;154-155
28. Carrozza M.J., Utley R.T., Workman J.L., Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet. 19:2003;321-329
29. Whiteway M., Szostak J.W. The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways. Cell. 43:1985;483-492
30. Jeong J.W., Bae M.K., Ahn M.Y., Kim S.H., Sohn T.K., Bae M.H., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 111:2002;709-720
31. Huang L.E., Willmore W.G., Gu J., Goldberg M.A., Bunn H.F. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J. Biol. Chem. 274:1999;9038-9044
32. Sogawa K., Numayama-Tsuruta K., Ema M., Abe M., Abe H., Fujii-Kuriyama Y. Inhibition of hypoxia-inducible factor 1 activity by nitric oxide donors in hypoxia. Proc. Natl. Acad Sci. U.S.A. 95:1998;7368-7373
33. Sumbayev V.V., Budde A., Zhou J., Brune B. HIF-1 alpha protein as a target for S-nitrosation. FEBS Lett. 535:2003;106-112
34. Hagen T., Taylor C.T., Lam F., Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science. 302:2003;1975-1978
35. Lando D., Peet D.J., Gorman J.J., Whelan D.A., Whitelaw M.L., Bruick R.K. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16:2002;1466-1471
36. Linke S, Stojkoski C, Kewley RJ, Booker GW, Whitelaw ML, Peet DJ. Substrate requirements of the oxygen-sensing asparaginyl hydroxylase factor inhibiting HIF. J Biol Chem 2004.
37. Safran M., Kaelin W.G. Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J. Clin. Invest. 111:2003;779-783
38. Chan H.M., La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114:2001;2363-2373
39. Kung A.L., Wang S., Klco J.M., Kaelin W.G., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:2000;1335-1340
40. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell Biol. 20:2000;402-415
41. Yasinska I.M., Sumbayev V.V. S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 549:2003;105-109
42. Bhattacharya S., Michels C.L., Leung M.K., Arany Z.P., Kung A.L., Livingston D.M. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. Genes Dev. 13:1999;64-75
43. Dial R., Sun Z.Y., Freedman S.J. Three conformational states of the p300 CH1 domain define its functional properties. Biochemistry. 42:2003;9937-9945
44. Freedman S.J., Sun Z.Y., Kung A.L., France D.S., Wagner G., Eck EckM.J. Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat. Struct Biol. 10:2003;504-512
45. Bhattacharya S., Ratcliffe P.J. Excited about HIF. Nat Struct Biol. 10:2003;501-503
46. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia- inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274:1999;32631-32637
47. Volmat V., Camps M., Arkinstall S., Pouyssegur J., Lenormand P. The nucleus, a site for signal termination by sequestration and inactivation of p42/p44 MAP kinases. J. Cell Sci. 114:2001;3433-3443
48. Sang N., Stiehl D.P., Bohensky J., Leshchinsky I., Srinivas V., Caro J. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 278:2003;14013-14019
49. Melchior F., Schergaut M., Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci. 28:2003;612-618
50. Seeler J.S., Dejean A. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4:2003;690-699
51. Tojo M., Matsuzaki K., Minami T., Honda Y., Yasuda H., Chiba T., et al. The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system. J. Biol. Chem. 277:2002;46576-46585
52. Berta M, Mazure N, Hattab M, Pouysségur J, Brahimi-Horn MC. Hypoxia-inducible factor-1a is modified by covalent attachment to SUMO. In: Keystone Symposia Conference: Biology of Hypoxia: The Role of Oxygen Sensing in Development, Normal Function and Disease, 2004.
53. Jiang H., Guo R., Powell-Coffman J.A. The Caenorhabditis elegans hif-1 gene encodes a bHLH-PAS protein that is required for adaptation to hypoxia. Proc. Natl. Acad Sci. U.S.A. 98:2001;7916-7921
54. Hirsila M., Koivunen P., Gunzler V., Kivirikko K.I., Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278:2003;30772-30780
55. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340
56. Huang J., Zhao Q., Mooney S.M., Lee F.S. Sequence determinants in hypoxia inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J. Biol. Chem. 13:2002;13
57. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490
58. Ryan H.E., Lo J., Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015
59. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 112:2003;645-657
60. Bilton R.L., Booker G.W. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur. J. Biochem. 270:2003;791-798
61. Wang F., Sekine H., Kikuchi Y., Takasaki C., Miura C., Heiwa O., et al. HIF-1alpha-prolyl hydroxylase: molecular target of nitric oxide in the hypoxic signal transduction pathway. Biochem. Biophys Res. Commun. 295:2002;657-662
62. Koivunen P, Hirsila M, Gunzler V, Kivirikko KI, Myllyharju J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 2003.
63. Bae M.K., Ahn M.Y., Jeong J.W., Bae M.H., Lee Y.M., Bae S.K., et al. Jab1 interacts directly with HIF-1alpha and regulates its stability. J. Biol. Chem. 277:2002;9-12
64. Isaacs J.S., Jung Y.J., Mimnaugh E.G., Martinez A., Cuttitta F., Neckers L.M. Hsp90 regulates a von Hippel-Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277:2002;29936-29944
65. Isaacs JS, Jung YJ, Neckers L. ARNT promotes oxygen-independent stabilization of hypoxia inducible factor-1 a by modulating an Hsp90-dependent regulatory pathway. J Biol Chem 2004.
66. Giaccia A., Siim B.G., Johnson R.S. HIF-1 as a target for drug development. Nat. Rev. Drug Discovery. 2:2003;803-811
67. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4:2003;457-467